|
Continuation of d10: section d information references the main component of the system.Other relevant device(s) are: product id: v nmc4337c200tu, serial/lot #: (b)(6), ubd: 03-sep-2022, udi#: (b)(4); product id: vnmf4034c185tu, serial/lot #: (b)(6), ubd: 25-sep-2022, udi#: (b)(4).Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Valiant navion stent grafts were implanted in the endovascular treatment of a 68mm taa.It was reported on an unknown date, a cta performed showed the endograft extending down to lower thoracic aorta, endograft was patent and the fusiform aneurysm of the aorta is larger than previous. 7.7cm transverse interval increase in the size of fusiform thoracoabdominal aneurysm.Intervention was performed approximately 1 year post the index procedure.3 non mdt stent grafts were implanted to reline the navion stent grafts to extend the graft just above the celiac artery and right axillary.The procedure also included a femoral bypass to right axillary femoral artery bypass w/ ptfe thoracic endograft placement w/o left subclavian artery coverage.Right axillary bypass w/ ptfe extension of thoracic endograft distally.A ct performed post the intervention was reported as good. per the physician the cause of the event could not determined. no additional clinical sequelae were provided and the patient is fine.
|